Synairgen plc (SNG) is a leading biotechnology business based in the UK. It opened the day at 234.26p after a previous close of 234p. During the day the price has varied from a low of 226p to a high of 240p. The latest price was 240p (25 minute delay). Synairgen is listed on the London Stock Exchange (LSE) and employs 14 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Synairgen's share price has had significant positive movement.
Its last market close was 173p, which is 91.33% up on its pre-crash value of 15p and 1,588.13% up on the lowest point reached during the March crash when the shares fell as low as 10.248p.
If you had bought £1,000 worth of Synairgen shares at the start of February 2020, those shares would have been worth £4,135.02 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £14,599.16.
|52-week range||5.5p - 260p|
|50-day moving average||185.9849p|
|200-day moving average||90.2278p|
|Wall St. target price||54p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-3.4p|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|3 months (2020-06-24)||451.72%|
|6 months (2020-03-24)||366.02%|
|Gross profit TTM||£105,000|
|Return on assets TTM||-55.37%|
|Return on equity TTM||-93.84%|
|Market capitalisation||£265.7 million|
TTM: trailing 12 months
We're not expecting Synairgen to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Synairgen's shares have ranged in value from as little as 5.5p up to 260p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Synairgen's is -3.1578. This would suggest that Synairgen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Synairgen has bucked the trend.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.